Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Quantitative analysis of amyloid β peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry

Oe, Tomoyuki, Ackermann, Bradley L., Inoue, Koichi, Berna, Michael J., Garner, Carlos O., Gelfanova, Valentina, Dean, Robert A., Siemers, Eric R., Holtzman, David M., Farlow, Martin R., Blair, Ian A.·2006·Rapid Communications in Mass Spectrometry

Abstract

The 40 and 42 amino‐acid residue forms of amyloid beta (A β 1–40 and A β 1–42 ) in cerebrospinal fluid (CSF) have been proposed as potential biomarkers of Alzheimer's disease (AD). Quantitative analyses of A β peptides in CSF have relied almost exclusively on the use of immunoassay‐based assays such as the enzyme‐linked immunosorbent assay (ELISA) procedure. However, due to the ability of the A β peptides to readily self‐aggregate or bind to other proteins and glassware, such analyses are extremely challenging. Analyses are further complicated by the potential of the peptides to undergo post‐translational modifications and the possibilities for cross‐reaction in the ELISA assays with endogenous components of the CSF. An approach based on liquid chromatography/tandem mass spectrometry (LC/MS/MS) has now been developed which overcomes these methodological issues. The key steps in implementing this new approach involved immunoaffinity purification coupled with the use of [ 15 N]‐labeled A β peptides as internal standards, a basic LC mobile phase, negative ion electrospray ionization, and a basic solvent for dissolving the peptides and washing the injection needle to prevent carryover of analytes during multiple injections on the LC/MS system. The validated method had limits of quantitation of 44 fmol/mL (200 pg/mL) for A β 1–42 and 92 fmol/mL (400 pg/mL) for A β 1–40 . An excellent correlation was found between the LC/MS/MS assay and an ELISA assay for A β 1–42 in human CSF (r 2 = 0.915), although less correlation was observed for A β 1–40 (r 2 = 0.644). Mean CSF A β 1–42 concentrations for samples collected 2 weeks apart from a limited number of AD patients provided additional confidence in the reproducibility of the LC/MS/MS assay. Concentrations for duplicate samples from AD patients were slightly higher than most previously reported values (mean 1.06 ± 0.25 ng/mL; n = 7). A β 1–40 concentrations in duplicate samples obtained from AD patients were also reproducible but were found to be slightly lower than most previously reported values (mean 6.36 ± 3.07 ng/mL; n = 7). Consistent with literature reports, mean A β 1–42 concentrations were found to be lower in AD patients compared with the normal subjects (mean 1.49 ± 0.59 ng/mL; n = 7), whereas there was no difference in A β 1–40 concentrations between AD patients and normal subjects (mean 5.88 ± 3.03 ng/mL; n = 7). The accuracy and precision of the LC/MS assay mean that it will be a useful complement to existing ELISA assays for monitoring therapeutic interventions designed to modulate CSF A β 1–42 concentrations in individual AD patients. Moreover, the introduction of stable isotope labeled internal standards offers the potential to achieve a more rigorous account of the influence of methodological effects related to sample collection and processing. Copyright © 2006 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/rcm.2787

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 166

Metadata

Authors
Oe, T., Ackermann, B. L., Inoue, K., Berna, M. J., Garner, C. O., Gelfanova, V., Dean, R. A., Siemers, E. R., Holtzman, D. M., Farlow, M. R., & Blair, I. A.
Venue
Rapid Communications in Mass Spectrometry
Publisher
Wiley
Published
2006-11-21
Volume
20
Issue
24
Pages
3723-3735
ISSN
  • 0951-4198 (ISSN-L)
  • 1097-0231
OpenAlex
W2107986159
Cited by
166
References
14
FWCI
6.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.